ALK and non-small cell lung carcinoma: The mutation rate of EGFR in NSCLC was 28.4% (147/517), PTEN was 9.5% (21/220), STK11 was 7.9%(8/101), EML4-ALK was 6.3% (15/239), KRAS was 5.4% (27/498), c-Met was 4.5% (20/448), PIK3CA was 4.4% (20/452), BRAF was 1.5% (7/452), DDR2 was 1.2% (2/166), and FGFR2 was 0.6% (1/165), respectively.